The broad role of ADAM17 inhibition on liver injury can also be seen in studies linking ADAM17 activity and hepatic stellate cell signaling in the setting of liver fibrosis in NASH (65) and ADAM17 in overall NAFLD development (66). The gene discussed is ADAM17; the disease is metabolic dysfunction-associated steatotic liver disease.